Nivolumab: all 1,113 studies that test it

Page 4 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial ColectomyTerminatedNCT03631641Phase 2Results posted
• CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseCompletedNCT03618641Phase 2Results posted
• pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate CancerActive, not recruitingNCT03600350Phase 2Results posted
• Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic CancerTerminatedNCT03599362Phase 2Results posted
• A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural EffusionTerminatedNCT03597009Phase 1/2Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasCompletedNCT03586999Phase 1/2Results posted
• Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedNCT03583086Phase 1/2Results posted
• A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerCompletedNCT03575793Phase 1/2Results posted
• Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCCompletedNCT03573947Phase 2Results posted
• Rucaparib and Nivolumab in Patients With Prostate or Endometrial CancerTerminatedNCT03572478Phase 1/2Results posted
• Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT03562507Phase 2Results posted
• Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder SparingCompletedNCT03558087Phase 2Results posted
• Nivolumab for Recurrent or Progressive IDH Mutant GliomasCompletedNCT03557359Phase 2Results posted
• COMbination of Bipolar Androgen Therapy and NivolumabCompletedNCT03554317Phase 2Results posted
• Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaTerminatedNCT03552380Phase 2Results posted
• Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder CancerCompletedNCT03532451Phase 1Results posted
• Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedNCT03523572Phase 1Results posted
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT03522246Phase 3Results posted
• Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell CancerCompletedNCT03521570Phase 2Results posted
• Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated MesotheliomaTerminatedNCT03502746Phase 2Results posted
• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell CarcinomaCompletedNCT03502330Phase 1Results posted
• BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)CompletedNCT03496662Phase 1/2Results posted
• Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSTerminatedNCT03495713Phase 2Results posted
• Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeCompletedNCT03493932Phase 1Results posted
• OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual DiseaseCompletedNCT03487666Phase 2Results posted
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaCompletedNCT03484819Phase 2Results posted
• Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the LiverCompletedNCT03472586Phase 2Results posted
• Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)CompletedNCT03453164Phase 1/2Results posted
• An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadTerminatedNCT03446040Phase 1/2Results posted
• Study of Nivolumab for Advanced Cancers in IndiaCompletedNCT03444766Phase 4Results posted
• PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRCCompletedNCT03442569Phase 2Results posted
• Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver CancerCompletedNCT03439891Phase 2Results posted
• Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskCompletedNCT03436862Phase 2Results posted
• REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedNCT03435640Phase 1/2Results posted
• Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaTerminatedNCT03430791Phase 2Results posted
• Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCTerminatedNCT03425331Phase 2Results posted
• Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for ChemoCompletedNCT03421652Phase 2Results posted
• Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsTerminatedNCT03420521Phase 2Results posted
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results posted
• An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has SpreadCompletedNCT03414983Phase 2/3Results posted
• Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast CancerCompletedNCT03414684Phase 2Results posted
• Regorafenib and Nivolumab Simultaneous Combination TherapyCompletedNCT03406871Phase 1Results posted
• Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)TerminatedNCT03406715Phase 2Results posted
• Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by SurgeryCompletedNCT03405155Phase 2Results posted
• Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyCompletedNCT03404960Phase 1/2Results posted
• Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersCompletedNCT03388632Phase 1Results posted
• METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinCompletedNCT03388190Phase 2Results posted
• SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung EffectsCompletedNCT03383302Phase 1/2Results posted
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT03382561Phase 2Results posted
• An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingNCT03377023Phase 1/2Results posted
• Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaCompletedNCT03370276Phase 1/2Results posted
• A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCompletedNCT03369223Phase 1/2Results posted
• Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated GlioblastomaCompletedNCT03367715Phase 2Results posted
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial CancersTerminatedNCT03363776Phase 1/2Results posted
• DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT03358719Phase 1Results posted
• Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive TherapyCompletedNCT03355560Phase 2Results posted
• A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03353675Phase 2Results posted
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced CancerTerminatedNCT03351231Phase 1/2Results posted
• Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck CancerCompletedNCT03349710Phase 3Results posted
• Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung CancerTerminatedNCT03348904Phase 3Results posted
• Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former SmokersActive, not recruitingNCT03347838Phase 2Results posted
• Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by SurgeryCompletedNCT03342911Phase 2Results posted
• Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHNActive, not recruitingNCT03341936Phase 2Results posted
• A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCompletedNCT03336216Phase 2Results posted
• Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03333746Phase 2Results posted
• Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT03325816Phase 1/2Results posted
• A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results posted
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid TumorsTerminatedNCT03311334Phase 1/2Results posted
• Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 TherapyTerminatedNCT03302247Phase 2Results posted
• A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic MelanomaTerminatedNCT03301636Phase 2Results posted
• Adoptive Cell Therapy Across Cancer DiagnosesCompletedNCT03296137Phase 1/2Results posted
• BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing CystectomyCompletedNCT03294304Phase 2Results posted
• Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell CarcinomaTerminatedNCT03278626Phase 1/2Results posted
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaTerminatedNCT03274258Phase 2Results posted
• Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)CompletedNCT03267498Phase 2Results posted
• Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a MelanomaTerminatedNCT03259425Phase 2Results posted
• A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsTerminatedNCT03251924Phase 1/2Results posted
• A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaCompletedNCT03250273Phase 2Results posted
• Nivolumab Plus Ipilimumab in Thyroid CancerCompletedNCT03246958Phase 2Results posted
• A Study of Nivolumab in Selected Uterine Cancer PatientsCompletedNCT03241745Phase 2Results posted
• Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaActive, not recruitingNCT03233347Phase 2Results posted
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaCompletedNCT03229278Phase 1Results posted
• Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerCompletedNCT03215810Phase 1Results posted
• A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCCompletedNCT03215706Phase 3Results posted
• Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaCompletedNCT03214250Phase 1/2Results posted
• A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaCompletedNCT03195491Phase 3Results posted
• A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT03195478Phase 1/2Results posted
• Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersCompletedNCT03190174Phase 1/2Results posted
• A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsCompletedNCT03184870Phase 1/2Results posted
• Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLCCompletedNCT03181308Phase 1Results posted
• Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS CancersTerminatedNCT03173950Phase 2Results posted
• Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerCompletedNCT03172624Phase 2Results posted
• Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)TerminatedNCT03168464Phase 1/2Results posted
• GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic CancerCompletedNCT03161379Phase 2Results posted
• A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has SpreadCompletedNCT03158272Phase 1Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerActive, not recruitingNCT03146650Phase 2Results posted
• A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCompletedNCT03143153Phase 3Results posted
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results posted

← Nivolumab overview